IRCCS Neuromed, Pozzilli 86077, Italy.
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina 04100, Italy.
Int J Mol Sci. 2021 Apr 6;22(7):3796. doi: 10.3390/ijms22073796.
Alterations in the metabolism of sphingolipids, a class of biologically active molecules in cell membranes with direct effect on vascular homeostasis, are increasingly recognized as important determinant in different vascular disorders. However, it is not clear whether sphingolipids are implicated in the pathogenesis of hypertension-related cerebrovascular and renal damage. In this study, we evaluated the existence of possible abnormalities related to the sphingolipid metabolism in the brain and kidneys of two well validated spontaneously hypertensive rat strains, the stroke-prone (SHRSP) and the stroke-resistant (SHRSR) models, as compared to the normotensive Wistar Kyoto (WKY) rat strain. Our results showed a global alteration in the metabolism of sphingolipids in both cerebral and renal tissues of both hypertensive strains as compared to the normotensive rat. However, few defects, such as reduced expression of enzymes involved in the metabolism/catabolism of sphingosine-1-phosphate and in the de novo biosynthetic pathways, were exclusively detected in the SHRSP. Although further studies are necessary to fully understand the significance of these findings, they suggest that defects in specific lipid molecules and/or their related metabolic pathways may likely contribute to the pathogenesis of hypertensive target organ damage and may eventually serve as future therapeutic targets to reduce the vascular consequences of hypertension.
鞘脂代谢的改变,一类细胞膜中具有直接影响血管内稳态的生物活性分子,越来越被认为是不同血管疾病的重要决定因素。然而,鞘脂是否参与与高血压相关的脑血管和肾脏损害的发病机制尚不清楚。在这项研究中,我们评估了两种经过充分验证的自发性高血压大鼠模型(卒中易发性 SHRSP 和卒中抵抗性 SHRSR)与正常血压的 Wistar Kyoto(WKY)大鼠相比,大脑和肾脏中与鞘脂代谢相关的可能异常的存在。我们的结果表明,与正常血压大鼠相比,两种高血压大鼠的大脑和肾脏组织中的鞘脂代谢都发生了全面改变。然而,仅在 SHRSP 中检测到少数缺陷,例如参与鞘氨醇-1-磷酸代谢/分解代谢以及从头生物合成途径的酶的表达降低。尽管需要进一步研究才能充分了解这些发现的意义,但它们表明特定脂质分子及其相关代谢途径的缺陷可能有助于高血压靶器官损害的发病机制,并最终可能成为减少高血压血管后果的未来治疗靶点。